NASDAQ$GBIO
Generation Bio Co · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Generation Bio reported Q3 2023 financial results and business highlights.
Generation Bio reported a net loss of $28.3 million for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities were $291.0 million as of September 30, 2023, which is expected to fund operations into 2026. The company also highlighted advances in its iqDNA and ctLNP platforms.
- Developed iqDNA to evade innate immune sensors, showing promising preclinical results in NHPs.
- Demonstrated highly selective T cell transduction with its ctLNP delivery system in a humanized mouse model.
- Cash balance of $291.0 million as of September 30, 2023, is expected to fund operations into 2026.
- Advanced iqDNA as its lead cargo across all programs, including its lead program in hemophilia A.
Headline financials
Revenue & EPS history
Generation Bio · Revenue · Quarterly
$2.15M
Revenue by segment
Generation Bio · $2.15M total across 1 segment · Q3 2023
- Collaboration revenue$2.15M—100.0%
Forward guidance
Generation Bio's cash position is expected to fund its operating plan into 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q3 2023
+3.8%
Avg return
Earnings day
+5.9%
Avg return
5 days after
+8.6%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+61.7%
Q2 2025
Best reaction
-19.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -3.3% | +11.0% | +2.7% | |
| Q2 2025 | +61.7% | +62.0% | +46.9% | |
| Q1 2025 | +4.5% | +0.4% | +4.0% | |
| Q4 2024 | -3.7% | -14.3% | -9.5% | |
| Q3 2024 | +8.7% | -0.5% | -40.8% | |
| Q2 2024 | -2.0% | -3.7% | -10.2% | |
| Q1 2024 | +18.4% | +16.4% | +1.9% | |
| Q4 2023 | +3.1% | +11.5% | +39.4% | |
| Q3 2023 | -1.7% | +7.7% | +46.2% | |
| Q2 2023 | -5.3% | -7.0% | +6.8% | |
| Q1 2023 | -5.0% | -2.7% | +0.4% | |
| Q4 2022 | -8.4% | -10.0% | +15.5% | |
| Q3 2022 | +12.2% | — | — | |
| Q2 2022 | +7.7% | — | — | |
| Q1 2022 | -19.7% | — | — | |
| Q4 2021 | +21.1% | — | — | |
| Q3 2021 | -1.5% | — | — | |
| Q2 2021 | -6.2% | — | — | |
| Q1 2021 | +0.3% | — | — | |
| Q4 2020 | -0.9% | — | — | |
| Q3 2020 | +8.5% | — | — | |
| Q4 2019 | -0.5% | — | — | |
| Q2 2020 | -0.5% | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro